The burden of illness associated with hepatocellular carcinoma in the United States-Reference-Cited by-同舟云学术

The burden of illness associated with hepatocellular carcinoma in the United States

Published:2009-01 Issue:1 Volume:50 Page:89-99
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Lang Kathleen,Danchenko Natalya,Gondek Kathleen,Shah Sonalee,Thompson David

Publisher

Elsevier BV

Subject

Hepatology

Reference49 articles.

1. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States;McGlynn;Cancer Epidemiol Biomarkers Prev,2006

2. Hepatocellular carcinoma;Erhardt;Dtsch Med Wochenschr,2002

3. Resection of extrahepatic hepatocellular carcinoma metastasis can result in long-term survival;Verhoef;Acta Chir Belg,2005

4. Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma;Bruix;Hepatology,2005

5. Bayer Corporate Web site. Investor News 2004: Bayer and Onyx Announce Phase II Results of Treatment with BAY 43-9006 in patients with advanced primary liver cancer. Available from: [accessed July 2008].

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial burden in a US cohort of patients with HCC;Hepatology Communications;2024-06

2. Describing financial toxicity among cancer patients in different income countries: a systematic review and meta-analysis;Frontiers in Public Health;2024-01-02

3. Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals;Clinical Gastroenterology and Hepatology;2024-01

4. Cost-effectiveness analysis: The missing factor in the management of HCC;Clinical Liver Disease;2024-01

5. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma;PLOS ONE;2023-10-05